S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
3 Drone Stocks That Can Lift Your Portfolio Higher
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
3 Quality Stocks On Track for Significant Dividend Increases
Is Gold Really Boring? (Ad)
5 Reasons Why Arcos Dorados Is A Perfect Investment for 2024
These Great-Grandparents Booked 51 Back-to-Back Cruises Because It's 'Cheaper Than a Retirement Home'
NASDAQ:NOVN

Novan (NOVN) Stock Forecast, Price & News

$0.02
0.00 (0.00%)
(As of 10/2/2023 ET)
Compare
Today's Range
$0.02
▼
$0.03
50-Day Range
$0.02
▼
$0.09
52-Week Range
$0.08
▼
$3.33
Volume
115,770 shs
Average Volume
602,421 shs
Market Capitalization
$644,345.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Novan MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
34,682.6% Upside
$8.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.72) to ($0.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

See Top Rated MarketRank™ Stocks Here

NOVN stock logo

About Novan (NASDAQ:NOVN) Stock

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

NOVN Price History

NOVN Stock News Headlines

September 28, 2023 | americanbankingnews.com
Novan (NASDAQ:NOVN) Receives New Coverage from Analysts at StockNews.com
September 8, 2023 | bizjournals.com
Novan reaches deals to sell assets in bankruptcy case
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 8, 2023 | msn.com
Firm Retention Summary: Novan
August 3, 2023 | msn.com
Novan (NOVN) Price Target Increased by 43.52% to 15.81
July 17, 2023 | marketwatch.com
Novan Shares Hit 52-Week Low After Bankruptcy Declaration
June 1, 2023 | bizjournals.com
Novan cuts 50% of its workforce to extend runway
June 1, 2023 | msn.com
Novan drops 13%, will reduce workforce by 50%
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
May 31, 2023 | markets.businessinsider.com
Novan To "Sharpen" Focus, Resources On Berdazimer Gel
May 31, 2023 | finance.yahoo.com
Novan Focuses Strategic Direction and Announces Restructuring
May 21, 2023 | fool.com
Novan (NASDAQ: NOVN)
May 17, 2023 | msn.com
Oppenheimer Maintains Novan (NOVN) Outperform Recommendation
May 16, 2023 | finance.yahoo.com
NOVN: Counting Down to PDUFA
May 15, 2023 | finanznachrichten.de
Novan, Inc.: Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 | markets.businessinsider.com
Novan earnings: here's what Wall Street expects
May 12, 2023 | msn.com
Earnings Preview: Novan
May 12, 2023 | msn.com
Novan Q1 2023 Earnings Preview
April 20, 2023 | finance.yahoo.com
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
April 3, 2023 | msn.com
Novan's Return On Capital Employed Overview
March 23, 2023 | finance.yahoo.com
Novan to Report Full Year 2022 Financial Results on March 30, 2023
March 7, 2023 | finance.yahoo.com
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
October 19, 2022 | reuters.com
JPMorgan names Qian as Southeast Asia equity capital markets chief - Reuters
October 14, 2022 | finance.yahoo.com
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference® - Yahoo Finance
October 14, 2022 | globenewswire.com
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference - GlobeNewswire
October 14, 2022 | finance.yahoo.com
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
October 6, 2022 | finance.yahoo.com
Global Acne Treatment Market (2022 Edition)– Analysis By Treatment, Treatment Modality, End-Users, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028) - Yahoo Finance
See More Headlines
Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Company Calendar

Last Earnings
5/15/2023
Today
10/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NOVN
CUSIP
N/A
CIK
1467154
Web
www.novan.com
Phone
(919) 485-8080
Fax
919-237-9212
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+34,682.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,310,000.00
Net Margins
-128.61%
Pretax Margin
-128.39%
Return on Equity
-700.28%
Return on Assets
-39.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.74
Quick Ratio
0.72

Sales & Book Value

Annual Sales
$24.71 million
Price / Sales
0.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
0.12

Miscellaneous

Outstanding Shares
28,015,000
Free Float
27,651,000
Market Cap
$644,345.00
Optionable
Not Optionable
Beta
-0.06
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Paula Brown Stafford M.P.H. (Age 58)
    Pres, CEO & Chairwoman
    Comp: $623.23k
  • Mr. John M. Gay CPA (Age 46)
    CFO, Principal Accounting Officer & Corp. Sec.
    Comp: $386.89k
  • Mr. John A. Donofrio Jr. (Age 56)
    Exec. VP & COO
    Comp: $602.51k
  • Dr. Carri Geer Ph.D.
    Sr. VP & CTO
  • Dr. Tomoko Maeda-Chubachi M.B.A.
    M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













NOVN Stock - Frequently Asked Questions

Should I buy or sell Novan stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NOVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares.
View NOVN analyst ratings or view top-rated stocks.

What is Novan's stock price forecast for 2023?

3 Wall Street analysts have issued 1-year target prices for Novan's shares. Their NOVN share price forecasts range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 34,682.6% from the stock's current price.
View analysts price targets for NOVN or view top-rated stocks among Wall Street analysts.

How have NOVN shares performed in 2023?

Novan's stock was trading at $1.46 at the beginning of the year. Since then, NOVN shares have decreased by 98.4% and is now trading at $0.0230.
View the best growth stocks for 2023 here.

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. The firm had revenue of $3.17 million for the quarter, compared to the consensus estimate of $6.19 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%. During the same period last year, the firm posted ($0.71) earnings per share.

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and Organigram (OGI).

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How do I buy shares of Novan?

Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $0.02.

How much money does Novan make?

Novan (NASDAQ:NOVN) has a market capitalization of $644,345.00 and generates $24.71 million in revenue each year. The company earns $-31,310,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The official website for the company is www.novan.com. The company can be reached via phone at (919) 485-8080, via email at cikkala@novan.com, or via fax at 919-237-9212.

This page (NASDAQ:NOVN) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -